CLEANOXO Malaysia - Englisch - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

cleanoxo

herbal science sdn. bhd. - semen plantaginis; rhizoma rhei; radix ledebouriellae; herba taraxaci; herba andrographitis -

ACARIZAX (American house dust mite extract and European house dust mite extract) SUBLINGUAL TABLET Australien - Englisch - Department of Health (Therapeutic Goods Administration)

acarizax (american house dust mite extract and european house dust mite extract) sublingual tablet

seqirus pty ltd - european house dust mite extract, quantity: 6 sq-hdm; american house dust mite extract, quantity: 6 sq-hdm - tablet - excipient ingredients: gelatin; sodium hydroxide; purified water; mannitol - allergic rhinitis acarizax is indicated for the treatment of house dust mite (hdm) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (? 12 years). allergic asthma acarizax is indicated for the treatment of hdm allergic asthma not well controlled by inhaled corticosteroids and associated with hdm allergic rhinitis in adults. patients? asthma status should be carefully evaluated before the initiation of treatment.

NUTRILIPID I.V. FAT EMULSION- soybean oil injection, solution Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

nutrilipid i.v. fat emulsion- soybean oil injection, solution

b. braun medical inc. - soybean oil (unii: 241atl177a) (soybean oil - unii:241atl177a) - soybean oil 20 g in 100 ml - nutrilipid® 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated.  nutrilipid 20% injection is contraindicated in patients who have: - known hypersensitivity to egg, soybean, peanut, or any of the active or inactive ingredients in nutrilipid 20% [see warnings and precautions (5.3)]. - severe disorders of lipid metabolism characterized by hypertriglyceridemia (serum triglyceride >1,000 mg/dl) [see warnings and precautions (5.7)]. there are no adequate or well controlled studies with nutrilipid 20% in pregnant women. additionally, animal reproduction studies have not been conducted with nutrilipid 20%. it is not known whether nutrilipid 20% can cause fetal harm when administered to a pregnant woman. nutrilipid 20% should be given to a pregnant woman only if clearly needed. it is not known whether nutrilipid 20% is present in hu

ALUSTAL HOUSE DUST MITES EXTRACT MAINTENANCE european house dust mite and american house dust mite 10.0 IR/mL injection suspension vial Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alustal house dust mites extract maintenance european house dust mite and american house dust mite 10.0 ir/ml injection suspension vial

stallergenes australia pty ltd - european house dust mite extract, quantity: 5 ir/ml; american house dust mite extract, quantity: 5 ir/ml - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; phenol; sodium chloride; water for injections; mannitol - treatment of patients with type 1 allergy (gell and coombs classification), particularly presenting as seasonal or perennial rhinitis, conjunctivitis, rhinoconjunctivitis, with or without associated asthma.

LANOXIN PG digoxin 62.5microgram tablet bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

lanoxin pg digoxin 62.5microgram tablet bottle

aspen pharma pty ltd - digoxin, quantity: 0.0625 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; povidone; indigo carmine; oxidised maize starch; rice starch - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Lanoxin Adult 500mcg/2mL injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

lanoxin adult 500mcg/2ml injection ampoule

aspen pharma pty ltd - digoxin, quantity: 0.25 mg/ml - injection, solution - excipient ingredients: citric acid monohydrate; dibasic sodium phosphate; propylene glycol; water for injections; ethanol - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Lanoxin Infants 50mcg/2mL injection ampoule Australien - Englisch - Department of Health (Therapeutic Goods Administration)

lanoxin infants 50mcg/2ml injection ampoule

aspen pharma pty ltd - digoxin, quantity: 25 microgram/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; citric acid; dibasic sodium phosphate; water for injections - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

OPTIMERGE PEANUT SEED DRESSING Australien - Englisch - APVMA (Australian Pesticides and Veterinary Medicines Authority)

optimerge peanut seed dressing

peanut company of australia limited - quintozene; captan - dust - quintozene benzene active 400.0 g/kg; captan carboximide active 400.0 g/kg - fungicide - peanut seed - pre-emergence rot | seedling blight or rot | seedling rot

SPORANOX ORAL SOLUTION Israel - Englisch - Ministry of Health

sporanox oral solution

j-c health care ltd - itraconazole - solution - itraconazole 10 mg/ml - itraconazole - itraconazole - sporanox oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. prevention of fungal infection during neutropenia of immunodeficient patients.

SPORANOX Itraconazole 10 mg/mL oral liquid bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sporanox itraconazole 10 mg/ml oral liquid bottle

janssen-cilag pty ltd - itraconazole, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: propylene glycol; hydroxypropylbetadex; saccharin sodium; purified water; caramel; sorbitol solution (70 per cent) (non-crystallising); sodium hydroxide; hydrochloric acid; flavour - sporanox oral solution is indicated for: * the treatment of oral and/or oesophageal candidiasis in hiv-positive or other immunocompromised patients. * prophylaxis of fungal infections in neutropenic patients.